Both Guggenheim's Yatin Suneja and Wainwright's Andrew Fein were more modest in their Neurocrine price target cuts, with the former shaving $2 off his target to $163 per share and the latter reducing ...

Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...

Neurocrine Biosciences Q4 earnings topped forecasts, but revenue slightly missed. Analysts see Ingrezza's long-term growth ...

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while ...

Wedbush analyst Laura Chico lowered the firm’s price target on Neurocrine (NBIX) to $147 from $157 and keeps an Outperform rating on the ...

Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...

Dr. Michael Rezak, MD, Ph.D., DBe, is a renowned neurologist specializing in the treatment of complex movement disorders such as Parkinson's Disease, ...

Reports Q4 revenue $627.7M, consensus $629.44M. “I’m proud of the tremendous progress we made last year with the continued growth of INGREZZA ...

We recently compiled a list of the 12 Best Low Risk High Growth Stocks to Invest In. In this article, we are going to take a look at where Neurocrine Biosciences, Inc.

Significantly increased risk for tardive dyskinesia seen with doses >75 mg/day at last prescription and as maximum dose.

Despite finishing strong across both its innovative and generic businesses in 2024, Teva’s cautious approach to the new year appears to have investors spooked. | Despite finishing strong in 2024, Teva ...